Your browser doesn't support javascript.
loading
Management of hot flushes in UK breast cancer patients: clinician and patient perspectives.
Fenlon, Deborah; Morgan, Adrienne; Khambaita, Priya; Mistry, Pankaj; Dunn, Janet; Ah-See, Mei-Lin; Pennery, Emma; Hunter, Myra S.
Afiliação
  • Fenlon D; a College of Health and Human Sciences , Swansea University , Swansea , UK.
  • Morgan A; b Independent Cancer Patient Voices , London , UK.
  • Khambaita P; c Pensions Policy Institute , King's College , London , UK.
  • Mistry P; d Warwick Medical School, Clinical Trials Unit , University of Warwick , Coventry, Coventry , UK.
  • Dunn J; d Warwick Medical School, Clinical Trials Unit , University of Warwick , Coventry, Coventry , UK.
  • Ah-See ML; e Mount Vernon Cancer Centre , London , UK.
  • Pennery E; f Breast Cancer Care , London , UK.
  • Hunter MS; g Institute of Psychiatry, Psychology and Neuroscience , Kings College London , London , UK.
J Psychosom Obstet Gynaecol ; 38(4): 276-283, 2017 12.
Article em En | MEDLINE | ID: mdl-28762873
ABSTRACT

INTRODUCTION:

Menopausal problems are among the most prevalent and distressing problems following breast cancer treatment, with 70% women experiencing hot flushes and night sweats (HFNS). A working party was set up to support the development of new research into the management of these problems.

METHODS:

We conducted surveys to explore the need as perceived by women with breast cancer and establish current UK management practices. A patient survey was conducted through a charity, Breast Cancer Care, and a health professional survey via the UK Breast Intergroup. The HFNS Problem Rating Scale was used, as well as specific questions addressing the aims of the study.

RESULTS:

Six hundred and sixty-five patients responded and 185 health professionals. Twenty-eight percent women had considered stopping adjuvant endocrine treatment because of HFNS, yet 34% had never been asked about HFNS by any health professional. The most commonly offered interventions were SSRIs, such as venlafaxine, yet only 25% patients had been offered these drugs. Cognitive behavioural therapy was rarely suggested (2%) despite good evidence.

DISCUSSION:

This study shows a lack of coherence in the management of HFNS in breast cancer survivors, which may lead to reduced adherence to adjuvant therapy. There is an urgent need to develop guidelines to support management of HFNS after breast cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estresse Psicológico / Neoplasias da Mama / Terapia Cognitivo-Comportamental / Inibidores Seletivos de Recaptação de Serotonina / Fogachos Tipo de estudo: Guideline / Qualitative_research Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: J Psychosom Obstet Gynaecol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estresse Psicológico / Neoplasias da Mama / Terapia Cognitivo-Comportamental / Inibidores Seletivos de Recaptação de Serotonina / Fogachos Tipo de estudo: Guideline / Qualitative_research Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: J Psychosom Obstet Gynaecol Ano de publicação: 2017 Tipo de documento: Article